Skip to NavigationSkip to content

Lilly the latest to open up data

Published on 04/06/14 at 10:39am
Lilly image

Eli Lilly is to begin sharing its clinical trial data with scientific researchers through a website housing information from several companies.

Access to the portal will only be granted after approval of a research proposal by an independent scientific review panel – a decision in which Lilly says it will not be involved.

Lilly will replace its current website, lillyclinicalstudydata.com – which the company says was an ‘interim’ solution - with the new one, clinicalstudydatarequest.com, which also contains data from Bayer, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Roche, Sanofi and ViiV Healthcare.

“Scientific advancements to improve patient care require the collaboration and creative thinking of researchers around the world,” says Tim Garnett, Lilly’s chief medical officer.

“By joining others in our industry to share clinical trial data with qualified researchers, we can quicken the pace of scientific advances needed to make life better,” he adds.

The anonymised data will be from Phase II, III or IV studies:

  • used as part of a regulatory approval submitted to the US Food and Drug Administration on or after 1999
  • with a first patient visit after January 1, 2007
  • in indications approved in both the US and EU with a first patient visit after January 1, 2014.

A number of pharma manufacturers, including Boehringer, Leo Pharma, Johnson and Johnson, Novartis and Sanofi have made moves towards greater transparency in the last few months.

They have pledged to proactively disclose higher levels of clinical data before new European laws come into force from 2016.

In April the European Parliament agreed that most new clinical trials will in the next two years become more open, and wants commercial and patent concerns to be put aside.

Transparency campaigners have welcomed these steps forward but as with recent similar pharma transparency offerings, they insist there are significant problems remaining.

Bad Pharma author Ben Goldacre said: “The new EU legislation is only concerned with new trials. It does not address the far bigger problem, that we still don’t have full reporting for all trials on the medicines we are using right now, today, medicines which we will continue to use for the foreseeable future.”

However, so far only GSK has gone the whole hog and signed up to the British transparency campaign, AllTrials.

Adam Hill

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches